ArticleFrontiers in psychiatry2026
Prospective observational study on behavioral monitoring, disease progression assessment, and screening model development for patients with depression using wearable devices and mobile phones: protocol.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Depression affects over 95 million people in China (lifetime prevalence 6.8%), yet traditional assessments rely on episodic, retrospective evaluations missing dynamic symptom fluctuations. While digital phenotyping offers continuous monitoring potential, feasibility questions remain for psychiatric populations: patient retention, data completeness, and technical challenges. This study assesses the feasibility of intensive multimodal digital phenotyping in routine outpatient care and explores digital phenotypes in major depressive disorder (MDD). Methods and analysis: This is a prospective protocol for a 12-month observational cohort study at Peking University Sixth Hospital that recruited 202 MDD outpatients and 100 healthy adults (aged 18-60 years) from August 2023 to February 2025, with follow-up ongoing through February 2026. The study evaluates practicality and reliability of multimodal digital phenotyping in real-world clinical settings. Data collection integrates: (1) high-frequency clinician-administered assessments using the 17-item Hamilton Depression Rating Scale (HAMD-17) at seven time points for patients with MDD and at baseline for healthy participants; (2) daily ecological momentary assessments and biweekly self-report questionnaires; (3) passive smartphone sensor data (physical activity, GPS, screen usage Results: MDD patients (n=202) were younger (30.8 ± 10.1 vs 42.8 ± 11.4 years) and more often unmarried (42.1% vs 15.0%) than healthy participants (n=100). Clinical-assessment completion declined from 100% (baseline) to 68.3% (Week 8). Among Android users (n=214), adequate EMA completion was 31.6% (MDD) vs 84.0% (healthy). Wearable adherence was 29.2% vs 70.0% (n=302). Conclusion: This feasibility study reveals marked compliance disparities between MDD patients and healthy participants, highlighting implementation barriers for real-world digital phenotyping in psychiatric populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.